Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H30N3O8.Cl |
Molecular Weight | 535.974 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[H][C@@]1(CCCCN1C(=O)OC[N+]2=CC=CC(=C2)C(=O)N[C@@H](CO)C(O)=O)[C@H](C(=O)OC)C3=CC=CC=C3
InChI
InChIKey=GONQEUJYYMYNMN-HWAJWLCKSA-N
InChI=1S/C25H29N3O8.ClH/c1-35-24(33)21(17-8-3-2-4-9-17)20-11-5-6-13-28(20)25(34)36-16-27-12-7-10-18(14-27)22(30)26-19(15-29)23(31)32;/h2-4,7-10,12,14,19-21,29H,5-6,11,13,15-16H2,1H3,(H-,26,30,31,32);1H/t19-,20+,21+;/m0./s1
Dexmethylphenidate is the dextrorotary form of methylphenidate. Dexmethylphenidate is marketed under the trade name Focalin. Focalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic
methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threoenantiomers. Focalin is a central nervous system (CNS) stimulant, available in three tablet strengths. Each tablet contains dexmethylphenidate hydrochloride 2.5, 5, or 10 mg for oral administration. Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment. Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Methylphenidate is a catecholamine reuptake inhibitor that indirectly increases catecholaminergic neurotransmission by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), which are responsible for clearing catecholamines from the synapse, particularly in the striatum and meso-limbic system.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
161.0 nM [Ki] | |||
206.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FOCALIN Approved UseFocalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in two placebo-controlled studies in patients meeting DSM-IV criteria for ADHD. Launch Date1.00560962E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23.72 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14747426 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
22.13 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14747426 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
10.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28590363 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
120.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14747426 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
131.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14747426 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
79.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28590363 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.68 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14747426 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.81 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14747426 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28590363 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
Other AEs: Vomiting, Agitation... Other AEs: Vomiting Sources: Page: p.11Agitation Tremor Hyperreflexia Muscle twitching Convulsions Euphoria Confusion Hallucinations Delirium Sweating Flushing Headache Hyperpyrexia Tachycardia Palpitations Cardiac arrhythmias Hypertension Mydriasis Mucosal dryness Rhabdomyolysis |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.7 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.7 |
Disc. AE: Twitching, Anorexia... AEs leading to discontinuation/dose reduction: Twitching (1%) Sources: Page: p.7Anorexia (1%) Insomnia (1%) Tachycardia (1%) Insomnia (1.8%) |
40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
Disc. AE: Cardiac disorders, Stroke... Other AEs: Increased blood pressure, Heart rate increased... AEs leading to discontinuation/dose reduction: Cardiac disorders (grade 3-5) Other AEs:Stroke (grade 3-5) Myocardial infarction (grade 3-5) Seizures Raynaud's phenomenon Increased blood pressure Sources: Page: p.1Heart rate increased Psychotic symptom (grade 3-5) Psychotic symptom Manic symptom Aggression Growth suppression Priapism Erection prolonged Vascular disorders Visual disturbance |
40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.8 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.8 |
Disc. AE: Feeling jittery, Anorexia... AEs leading to discontinuation/dose reduction: Feeling jittery (1.8%) Sources: Page: p.8Anorexia (1.2%) Anxiety (1.2%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agitation | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Cardiac arrhythmias | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Confusion | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Convulsions | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Delirium | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Euphoria | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Flushing | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Hallucinations | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Headache | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Hyperpyrexia | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Hyperreflexia | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Hypertension | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Mucosal dryness | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Muscle twitching | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Mydriasis | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Palpitations | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Rhabdomyolysis | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Sweating | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Tachycardia | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Tremor | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Vomiting | 40 mg single, oral (min) Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.11 |
|
Anorexia | 1% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.7 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.7 |
Insomnia | 1% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.7 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.7 |
Tachycardia | 1% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.7 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.7 |
Twitching | 1% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.7 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.7 |
Insomnia | 1.8% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.7 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.7 |
Aggression | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
|
Erection prolonged | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
|
Growth suppression | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
|
Heart rate increased | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
|
Increased blood pressure | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
|
Manic symptom | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
|
Priapism | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
|
Psychotic symptom | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
|
Vascular disorders | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
|
Visual disturbance | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
|
Raynaud's phenomenon | Disc. AE | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
Seizures | Disc. AE | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
Psychotic symptom | grade 3-5 | 40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
Cardiac disorders | grade 3-5 Disc. AE |
40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
Myocardial infarction | grade 3-5 Disc. AE |
40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
Stroke | grade 3-5 Disc. AE |
40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.1 |
Anorexia | 1.2% Disc. AE |
40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.8 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.8 |
Anxiety | 1.2% Disc. AE |
40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.8 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.8 |
Feeling jittery | 1.8% Disc. AE |
40 mg 1 times / day multiple, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.8 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Sources: Page: p.8 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 11.0 |
no | |||
Page: 11.0 |
no | |||
Page: 11.0 |
no | |||
Page: 11.0 |
no | |||
Page: 11.0 |
no | |||
Page: 11.0 |
no | |||
Page: 11.0 |
no | no (co-administration study) Comment: Clinically, methylphenidate coadministration did not increase plasma concentrations of the CYP2D6 substrate desipramine. Page: 11.0 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15082749/ Page: - |
no | |||
Sources: https://www.pharmgkb.org/pmid/16621932 Page: - |
weak | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12215063/ Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
[Prescribing ritalin in combined modality management of hyperactivity with attention deficit]. | 2001 Sep-Oct |
|
A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects. | 2004 Feb |
|
Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder. | 2006 |
|
The nonmedical use of prescription ADHD medications: results from a national Internet panel. | 2007 Oct 31 |
|
Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. | 2008 May |
|
Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride. | 2009 |
|
Psychopharmacology of ADHD in pediatrics: current advances and issues. | 2009 |
|
Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer. | 2009 Jun 29 |
|
A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). | 2009 Jun 8 |
|
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. | 2009 Nov |
|
Dexmethylphenidate for attention deficit hyperactivity disorder. | 2009 Nov |
|
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. | 2010 Sep 3 |
Patents
Sample Use Guides
Focalin (Dexmethylphenidate) is administered twice daily, at least 4 hours apart. Focalin may be administered with or without food. The recommended starting dose of Focalin for patients who are not currently taking racemic
methylphenidate, or for patients who are on stimulants other than methylphenidate, is 5
mg/day (2.5 mg twice daily).
Dosage may be adjusted in 2.5 to 5 mg increments to a maximum of 20 mg/day (10 mg twice daily). In general, dosage adjustments may proceed at approximately weekly intervals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21129986
Dexmethylphenidate inhibition [3H]dopamine uptake at human DAT expressed in mouse N2A cells with IC50 156 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2562177
Created by
admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
|
PRIMARY | |||
|
DTXSID901336633
Created by
admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
|
PRIMARY | |||
|
134823897
Created by
admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
|
PRIMARY | |||
|
300000005364
Created by
admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
|
PRIMARY | |||
|
FN54BT298Y
Created by
admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
|
PRIMARY | |||
|
1996626-30-2
Created by
admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
|
PRIMARY | |||
|
EF-151
Created by
admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
|
PRIMARY | |||
|
FN54BT298Y
Created by
admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
|
PRIMARY | |||
|
C170377
Created by
admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
|
PRIMARY | |||
|
Serdexmethylphenidate
Created by
admin on Sat Dec 16 13:44:31 UTC 2023 , Edited by admin on Sat Dec 16 13:44:31 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD